Nanomaterial-assisted theranosis of bone diseases

Zheng, Kai; Bai, Jiaxiang; Yang, Huilin; Xu, Yaozeng; Pan, Guoqing; Wang, Huaiyu; Geng, Dechun

doi:10.1016/j.bioactmat.2022.12.014

Cited by 15 publications

(14 citation statements)

References 339 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Researchers developed various drug delivery systems to carry small interfering RNA (siRNA), microRNA, and plasmid DNA, because traditional anti-inflammatory medications always need frequent and prolonged administration. [196][197][198] Target gene can be downregulated by siRNA via RNA interference, which is a method for regulating gene expression by mRNA cleavage or translational inhibition. IL-1𝛽 is a key cytokine in the induction and development of RA, Song et al developed lipidoid-polymer hybrid NPs to carry siRNA (named FS14-NP/siIL-1𝛽) against IL-1𝛽 to macrophages, and thus lower the expression of proinflammatory cytokines in RA.…”

Section: Cytokine Inhibitionmentioning

confidence: 99%

Tailoring Biomaterials Ameliorate Inflammatory Bone Loss

Cheng,

Wang,

Zhou

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Inflammatory diseases, such as rheumatoid arthritis, periodontitis, chronic obstructive pulmonary disease and celiac disease, disrupt the delicate balance between bone resorption and formation, leading to inflammatory bone loss. Conventional approaches to tackle this issue encompass pharmaceutical interventions and surgical procedures. Nevertheless, pharmaceutical interventions exhibit limited efficacy, while surgical treatments impose trauma and significant financial burden upon patients. Biomaterials show outstanding spatiotemporal controllability, possess a remarkable specific surface area, and demonstrate exceptional reactivity. In the present era, the advancement of emerging biomaterials has bestowed upon us more efficacious solutions for combatting the detrimental consequences of inflammatory bone loss. In this review, we list the advances of biomaterials for ameliorating inflammatory bone loss. Additionally, we summarize the advantages and disadvantages of various biomaterials‐mediated strategies. Finally, we analyze the challenges and perspectives of biomaterials. This review aims to provide new possibilities for developing more advanced biomaterials towards inflammatory bone loss.This article is protected by copyright. All rights reserved

show abstract

Section: Cytokine Inhibitionmentioning

confidence: 99%

Tailoring Biomaterials Ameliorate Inflammatory Bone Loss

Cheng,

Wang,

Zhou

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Overall, bifunctional tissue engineering scaffolds show great promise as potential therapy for bone tumors and large bone defects. With further research and development, these scaffolds could provide a more effective and targeted approach to treating bone tumors and promoting bone repair . Ceramic materials, such as hydroxyapatite (HAp) , and calcium phosphate, are good candidates for the controlled delivery of anticancer drugs and for minimizing their side effects.…”

Section: Introductionmentioning

confidence: 99%

Strategically Designed Bifunctional Polydopamine Enwrapping Polycaprolactone-Hydroxyapatite-Doxorubicin Composite Nanofibers for Osteosarcoma Treatment and Bone Regeneration

Rezk,

Lee,

Kim

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

This study presents a new multifunctional nanofibrous drug delivery system to provide effective combination therapy with enormous potential for the treatment of osteosarcoma. We developed a composite nanofiber scaffold comprising poly(ε-caprolactone) (PCL) and hydroxyapatite (HAp)-loaded doxorubicin (DOX) coated with polydopamine (PDA) to combine cancer cell inhibition with bone tissue regeneration. DOX was conjugated with HAp and then mixed with a PCL solution to prepare a PCL/ HAp−DOX (labeled PCLDH) nanofiber. Then, in situ polymerization of PDA on the PCLDH occurred to produce the PCLDH@PDA composite nanofiber. The morphology, XRD, FT-IR, wettability, photothermal characteristics, cumulative drug release, and in vitro bioactivities were evaluated. We found that the PDA coating not only enhanced the hydrophilic properties but also controlled drug release. The PCLDH@PDA composite scaffold significantly suppressed the proliferation of bone cancer cells initially and, consequently, improved the adhesion and proliferation of human mesenchymal stem cells (hMSCs). The PDA coating boosted the composite scaffold's bioactivity, as demonstrated through ALP activity, ARS assay, and biomineralization results. This strategy offers a promising dual-function scaffold to treat residual cancer and reconstruct defects after osteosarcoma surgery.

show abstract

“…Над повышением эффективности и безопасности антирезорбтивной терапии ОП и усовершенствованием методов фармакологической коррекции нарушений костного обмена при ОП работают ведущие научные школы как в России, так и за рубежом. В последние годы были открыты и проходят клинические испытания несколько новых молекул и методов лечения ОП, об эффективности и безопасности которых говорить пока рано [8][9][10][11][12][13]. Кроме того, накапливаются данные о клинических особенностях и отдаленных результатах применения давно известных препаратов при длительном ведении больных ОП [14,15].…”

Section: Introductionunclassified

Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice

Sivordova¹,

Polyakova²,

Papichev³

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The development of osteoporosis (OP) increases healthcare costs and often leads to disability of patients. In this regard, the search for ways to improve the effectiveness of OP treatment is very relevant. Today, there is a wide range of drugs for the effective correction of bone metabolism. However, low patient compliance in real clinical practice significantly reduces the effectiveness of therapy.Aim. To study the effect of patient compliance on the effectiveness of Zoledronic acid and Denosumab in OP in real clinical practice.Materials and methods. Study design: a retrospective analysis of outpatient records of 300 patients with OP, who were prescribed Zoledronic acid or Denosumab in 2019, with a prospective analysis of adherence to therapy for 3 years.Results. It was revealed that 12% of patients did not start pathogenetic therapy for OP (control group). 88% (264 patients) started pathogenetic therapy: of these, 22.33% (67 patients) preferred therapy with Denosumab; 65.67% (197 patients) – Zoledronic acid. After 1 year, therapy with Denosumab 19.4%, Zoledronic acid – 19.29% was discontinued. More than 1 month late with the next injection of the drug: Denosumab – 25.37%, Zoledronic acid – 16.24% of patients. Only 55.22% who received Denosumab and 64.47% who received Zoledronic acid fully complied with the recommendations. Most often, a violation of the schedule of drug administration was observed in patients over 75 years of age, alone, with impaired cognitive status. Discontinuation of therapy with Denosumab or violation of the schedule of its administration led to an increase in the level of bone resorption (C-telopeptide type I collagen (CTX-1)). During therapy with Zoledronic acid, there was no increase in CTX-1. In addition, the cost of course treatment with Zoledronic acid is 2–3 times less than with Denosumab.Conclusion. In real clinical practice, zoledronic acid has clinical and pharmacoeconomic advantages, especially in patients with expected low adherence to OP therapy.

show abstract

Nanomaterial-assisted theranosis of bone diseases

Cited by 15 publications

References 339 publications

Tailoring Biomaterials Ameliorate Inflammatory Bone Loss

Tailoring Biomaterials Ameliorate Inflammatory Bone Loss

Strategically Designed Bifunctional Polydopamine Enwrapping Polycaprolactone-Hydroxyapatite-Doxorubicin Composite Nanofibers for Osteosarcoma Treatment and Bone Regeneration

Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice

Contact Info

Product

Resources

About